Odefsey

Active Ingredient(s): Emtricitabine + Rilpivirine + Tenofovir Alafenamide
FDA Approved: * March 1, 2016
Pharm Company: * GILEAD SCIENCES INC
Category: HIV / AIDS

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Odefsey Overview

Tenofovir alafenamide (INN/USAN; trade name Vemlidy) is a nucleotide reverse transcriptase inhibitor and a prodrug of tenofovir. It was developed by Gilead Sciences for use in the treatment of HIV infection and chronic hepatitis B, and is applied in the form of tenofovir alafenamide fumarate (TAF). Closely related to the commonly used reverse-transcriptase inhibitor tenofovir disoproxil fumarate (TDF), TAF has greater antiviral activity and better distribution into lymphoid tissues than that ...

Read more Odefsey Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Tenofovir_alafenamide

Recent Odefsey Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Emtricitabine + Rilpivirine + Tenofovir Alafenamide
  • Tablet: 200 + 25 + 25mg, 200mg + 25mg + 25mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Odefsey: (3 results)

Sorted by National Drug Code
  • 50090-2340 Odefsey Oral Tablet by A-s Medication Solutions
  • 61958-2101 Odefsey Oral Tablet by Gilead Sciences, Inc.
  • 70518-0695 Odefsey Oral Tablet by Remedyrepack Inc.

Drugs with one or more similar ingredients: (22 results)






Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 21 January 2019.

We are committed to your privacy.

Copyright © 2005-2019 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA